Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
Roberto Mina, Anne K. Mylin, Hisayuki Yokoyama, Hila Magen, Winfried Alsdorf, Monique C. Minnema, Leyla Shune, Iris Isufi, Simon J. Harrison, Urvi A. Shah, Jordan M. Schecter, Martin Vogel, Nikoletta Lendvai, Katharine S. Gries, Eva G. Katz, Ana Slaughter, Carolina Lonardi, Jane Gilbert, Quanlin Li, William Deraedt, Octavio Costa Filho, Nitin Patel, Erika Florendo, Lionel Karlin, Katja Weisel
Topics & Concepts
MedicinePomalidomideLenalidomideInternal medicineMultiple myelomaClinical endpointPopulationThalidomideBortezomibClinical trialSurgeryOncologyEnvironmental healthMultiple Myeloma Research and TreatmentsCAR-T cell therapy researchCancer Immunotherapy and Biomarkers